{
    "clinical_study": {
        "@rank": "105957", 
        "acronym": "UNRAVEL", 
        "arm_group": [
            {
                "arm_group_label": "Ranibizumab (Lucentis)", 
                "arm_group_type": "Experimental", 
                "description": "102 patients with an eligible study eye will be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab will be used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections will be performed (Baseline, Month 1, Month 2)."
            }, 
            {
                "arm_group_label": "Aflibercept (Eylea)", 
                "arm_group_type": "Active Comparator", 
                "description": "102 patients with an eligible study eye will be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept will be used for intravitreal injection admistered by an unblinded injecting physician. 3 injections will be performed (Baseline, Month 1, Month 2)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess systemic VEGF level in patients with neovascular Age-related Macular\n      Degeneration following treatment with Ranibizumab or Aflibercept"
        }, 
        "brief_title": "UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neovacular Age-related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed AMD\n\n          -  No previous treatment received for diagnosed AMD\n\n          -  Visual Acuity 6/7.5 to 6/96\n\n        Exclusion Criteria:\n\n          -  standard exclusion criteria for anti-VEGF treatment\n\n          -  Visual Acuity <6/96\n\n          -  nAMD in both eyes, or any condition in other eye which may require anti-VEGF\n             treatment during study period\n\n          -  other disease in candidate eye which could compromise visual acuity or require\n             medical/surgical intervention during study period\n\n          -  participation to other clinical study with 'not approved' treatment within a year\n             prior to UNRAVEL study participation.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01988662", 
            "org_study_id": "CRFB002A-MAX-IL-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ranibizumab (Lucentis)", 
                "Aflibercept (Eylea)"
            ], 
            "description": "Blood measurement", 
            "intervention_name": "VEGF level assessment", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "nAMD, VEGF, VEGF agent, BCVA, CRT, Ranibizumab, Lucentis, Aflibercept, Eylea", 
        "lastchanged_date": "November 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lin-Ko", 
                        "country": "Taiwan", 
                        "zip": "33305"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment na\u00efve Neovascular Age-related Macular Degeneration (nAMD) Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ministry of Health", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Malaysia: Ministry of Health", 
                "Singapore: Health Sciences Authority", 
                "Taiwan: Department of Health", 
                "Thailand: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent reduction in blood VEGF level is calculated as the difference in blood VEGF level mesured after 3 month of anti-VEGF agent IVT treatment (Ranibizumab or Aflibercept) when compared to baseline blood VEGF level.", 
            "measure": "Percent reduction in blood VEGF at month 3 following intravitreal (IVT) injection of anti-VEGF agent", 
            "safety_issue": "Yes", 
            "time_frame": "Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01988662"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood VEGF measurement performed at all visits and compared to baseline level", 
                "measure": "Percent reduction in blood VEGF level overtime", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to month 3"
            }, 
            {
                "description": "VEGF level and anti-VEGF concentration measured in the blood at each single visit, including pre- and post-dose measurement during the dosing visits.", 
                "measure": "Correlation between blood detected VEGF level and measured concentration of anti-VEGF agent overtime", 
                "safety_issue": "Yes", 
                "time_frame": "baseline through month 3"
            }, 
            {
                "description": "BCVA score is assessed on study eye at every study visit based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts at a testing distance of 4 meters. An increase in score indicates an improvement in acuity", 
                "measure": "Mean change from baseline in Best Corrected Visual Acuity (BCVA) of the study eye over time", 
                "safety_issue": "No", 
                "time_frame": "baseline through Month 3"
            }, 
            {
                "description": "Central Retinal Thickness in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area.", 
                "measure": "mean change in central retinal thickness (CRT) of the study eye over time", 
                "safety_issue": "No", 
                "time_frame": "baseline through Month 3"
            }, 
            {
                "description": "Number of reported ocular and systemic AEs", 
                "measure": "Number of ocular and systemic Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Month 3"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}